Dr. Dahyeon Kang is an Assistant Professor at the University of Washington School of Medicine. She earned her doctoral degree from the University of Illinois at Urbana-Champaign, where her work focused on the etiology of alcohol and substance use disorders through multimodal research methods, including alcohol administration, neuroimaging, transdermal biosensors, and ecological momentary assessments. At the University of Washington’s Department of Psychiatry, Dr. Kang investigates how individual and social factors interact to influence alcohol and cannabis use behaviors.
As a clinical and quantitative psychologist, my work bridges statistical practice and psychological theory to better identify for whom, under what conditions, and why substance-related health disparities are greatest across development. My substantive research seeks to understand how individual differences in stress and developing self-regulation shape substance use and disorder from adolescence through young adulthood, and how these associations explain substance use disparities among sexual and gender minoritized communities. Stemming from this work, my methodological research is centered on improving the analysis and interpretation of nonlinear effects spanning parametric and non-parametric methodologies.
I am a behavioral neuroscientist who earned my PhD from Rutgers University and completed a postdoc here, in the Psychiatry and Behavioral Sciences Department at the University of Washington. My lab, located in the MIRECC at VA Puget Sound, aims to identify the neural mechanisms underlying substance use disorders and maladaptive decision making.
My primary focus is studying the neurobiological consequences and predictors of chronic fentanyl use. To accomplish this, I utilize cutting-edge in-vivo optical neuroscience tools (photometry, optogenetics, miniscopes) along with a newly developed oral-fentanyl self-administration model for rats and mice. I am also the lead developer for DeepSqueak, a popular software package for bioacoustics analysis that integrates machine-vision algorithms with an intuitive graphical interface to accelerate animal communication research.
My primary areas of research include artificial intelligence, AI/machine ethics, behavioral health technologies, telemedicine, telehealth, forensic psychology, and military and Veteran population health. I’ve consulted widely on the topic of military and veteran health and technology in healthcare and have helped to develop national guidelines for telemental health, clinical best practices for technology-based treatments, and standards for human-AI interaction transparency. My vision is to build, and help others to build, technologies that help promote behavioral change and that improve the lives of people.
Personal Statement
Over the past 20 years, my research has focused on the genetics of schizophrenia and neurodegenerative disorders, particularly on the use of clinical phenotyping and innovative genomic technologies to elucidate the complex genetic architecture underlying schizophrenia and Alzheimer’s disease (AD). I served as the Director of the Geriatric Research, Education, and Clinical Center (GRECC) at the VA Puget Sound Health (VAPS) from 2011-2022, in order to focus on my research on Alzheimer’s Disease and related disorders. My current research interests are two-pronged: 1) develop machine learning models in VA’s vast electronic health records in order to assign ADRD probability scores in older Black and White Veterans; and 2) use mobile health devices to promote early diagnosis of dementia with Lewy bodies. In In these capacities, I direct multidisciplinary efforts to better understand the biology, genetics, etiology, prevention, and treatment of these disorders, and I provide clinical expertise for the differential diagnosis of neurodegenerative disorders and treatment of behavioral disturbances in dementias.
Personal Statement
My clinical interests include diagnosis and psychopharmacology of complex mood and anxiety disorders and psychosis. My research program investigates the molecular neuroscience of behavior using animal models with a focus on the involvement of the serotonin system and the neurocircuitry and plasticity involved in stress and addiction.
My lab uses rat and mouse models to investigate stress and addiction mechanisms. The lab is unusual because we pursue a very broad range of methods, including molecular, cellular, neuroanatomical, and behavioral levels of organization. We have focused on serotonin receptors historically but increasingly we are using novel molecular and genetic tools to dissect the involvement of key neural circuits in behavioral models of stress and/or addiction.
The main strategies include a range of behavioral models, intersectional transgenic and viral-mediated gene transfer manipulations of gene expression, neuropharmacology, engineered receptors (DREADDs), fiber photometry, calcium imaging, two-photon microscopy, RNAseq and RTqPCR (using RiboTag pull-down). We are trying to push the envelope in developing and using methods that allow us very precise manipulations or readouts from specific pathways such as the projections from nucleus accumbens to ventral tegmentum or lateral habenula to dorsal raphe nucleus. We are also exploring the role of microglia, the innate immune cells in the brain, during early stages of drug and alcohol withdrawal in advance of typical activation of neuroinflammation.
